George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,711.80
Bid: 1,711.80
Ask: 1,712.00
Change: 6.60 (0.39%)
Spread: 0.20 (0.012%)
Open: 1,701.60
High: 1,713.00
Low: 1,699.40
Prev. Close: 1,705.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-FTSE 100 ekes out gains on pharma strength

Mon, 28th Oct 2019 09:17

* FTSE 100 up 0.1%, FTSE 250 up 0.5%

* Astra, GSK offer most support to main bourse

* HSBC falls after profit miss

* Cairn Energy biggest midcap faller
(Adds company news items, changes analyst quote, updates share
moves)

By Muvija M and Shashwat Awasthi

Oct 28 (Reuters) - The exporter-laden FTSE 100
recovered from early losses on Monday despite a rebound in
sterling, boosted by gains in leading drug stocks and as
prospects for a U.S.-China trade agreement powered miners and
industrials.

The blue chip index closed 0.1% higher, lagging peers on
Wall Street and in Europe as a near 4% drop in HSBC
after an underwhelming earnings update, and a slide in dollar
earners, capped gains.

The more domestically-focused FTSE 250 outperformed
with a 0.5% rise ahead of a parliamentary vote on Prime Minister
Boris Johnson's demand for a general election.

AstraZeneca climbed as much 3.6% after saying a
combination of its cancer drug, Imfinzi, along with chemotherapy
helped curb progression of lung cancer in a late-stage study.
The shares ended up 1%.

In the same sector GlaxoSmithKline added 2.2% after
the company said it had begun a late-stage study of its
experimental antibiotic in patients with urinary tract
infections and gonorrhoea.

Gains of between 1.3% and 2.2% in Glencore, BHP
and Anglo American powered the mining sector
, exposed to the international trade scenario, to a
one-month high after U.S. President Donald Trump said he
expected to sign a significant part of a trade deal with China
ahead of schedule.

EARNINGS TARGET

By contrast HSBC shares suffered their biggest
one-day loss in eight months as the bank's third-quarter profit
missed expectations and it dropped its 2020 earnings target amid
macro-economic uncertainties.

The update dragged a sub-index of banks 2.4%
lower.

Financial companies have also had to adjust to a lower
interest rate environment this year as central banks globally
move to loosen monetary policies to cushion an impact from trade
tensions.

To that end, markets are also keeping a close eye on the
U.S. Federal Reserve's meeting this week for more support to the
slowing global economy.

"We see the Fed cutting rates this week and possibly again
next year, as it seeks to provide insurance against a broad
economic slowdown", BlackRock analysts wrote in their weekly
note.

In addition, UK firms face a lack of clarity at home as
lawmakers and Prime Minister Boris Johnson feud over Brexit.
Earlier in the day, the European Union agreed a three-month
flexible delay to the Oct. 31 exit date.

Among midcaps, there was an 8.1% plunge in Cairn Energy
after the oil and gas explorer abandoned an offshore
well in Mexico.

Aston Martin, which has plunged nearly 80% from its
2018 debut, dropped 8.5% after Bank of America Merrill Lynch
downgraded the stock.
(Reporting by Muvija M and Shashwat Awasthi
Additional reporting by Safia Infant in Bengaluru
Editing by Arun Koyyur and David Holmes
)

More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.